MIC range and mode for telavancin Gram-positive pathogens using 6 CLSI and European susceptibility testing methods
| Telavancin MIC range (mode) mg/L |
||||
|---|---|---|---|---|
| Methoda | STA | ENT | STR | CJ |
| 1 (MD) | 0.015–1 | 0.015–8 | 0.004–0.25 | 0.008–0.03 |
| (0.12) | (0.25 and 4b) | (0.015) | (0.015) | |
| 2 (MD) | 0.03–1 | 0.03–8 | 0.008–0.25 | 0.015–0.06 |
| (0.12) | (0.06 and 4b) | (0.03) | (0.03) | |
| 3 (AD) | 0.06–2 | 0.03–4 | 0.015–0.12 | 0.015–0.12 |
| (0.12) | (0.06 and 2b) | (0.12) | (0.06) | |
| 4 (AD) | 0.03–1 | 0.03–4 | 0.015–0.12 | 0.015–0.03 |
| (0.12) | (0.06 and 4b) | (0.03) | (0.03) | |
| 5 (AD) | 0.03–1 | 0.03–4 | 0.015–0.06 | 0.015–0.03 |
| (0.06) | (0.06 and 2b) | (0.03) | (0.015) | |
| 6 (AD) | 0.06–2 | 0.03–4 | 0.015–0.12 | 0.015–0.06 |
| (0.12) | (0.06 and 2b) | (0.12) | (0.03) | |
NL>
a
Methods: 1. CLSI-DIN-EUCAST (MD); 2. SRGA (MD); 3. DIN (AD); 4. BSAC (AD); 5, SRGA (AD); 6. CLSI-CASFM-EUCAST (AD).
b
E. faecalis with VanA phenotype.